Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an update.
Rhythm Biosciences Ltd announced the departure of its Chief Financial Officer, Mr. Todd Perkinson, effective December 19, 2025. This change in leadership comes as the company continues to focus on its mission of providing innovative diagnostic solutions for early cancer detection. The departure could impact the company’s financial strategy and operations, but the board expressed gratitude for Mr. Perkinson’s contributions.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden by partnering with global entities for the commercialization and distribution of its solutions. Its products include the ColoSTAT® test for colorectal cancer detection and the geneType™ platform for comprehensive genetic risk assessments across multiple diseases.
Average Trading Volume: 334,254
Technical Sentiment Signal: Sell
Current Market Cap: A$26.62M
For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.